This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schuh, J. C.L. Articles by Morrissey, P. J. Search for Related Content PubMed PubMed Citation Articles by Schuh, J. C.L. Articles by Morrissey, P. J. Social Bookmarking                   What's this?

Development of a Recombinant Growth Factor and Fusion Protein: Lessons from GM-CSF

Department of Molecular Immunology, Immunex Corporation, Seattle, Washington 98101, Immunex Corporation, 51 University Street, Seattle, Washington 98101, jschuh{at}immunex.com.

Philip J. Morrissey

Department of Molecular Immunology, Immunex Corporation, Seattle, Washington 98101

Several colony stimulating factors (CSFs) and cytokines have been successfully used to mobilize hematopoietic cells during myeloablative therapy, bone marrow failure, and transplantation and to provide supportive treatment during sepsis. The use of yeast-derived recombinant human granulocyte-macrophage CSF (rhuGM-CSF) and its interleukin-3 fusion protein, PIXY321, provides an example of issues associated with development programs for recombinant hematopoietic growth factors. Species specificity of rhuGM-CSF, different bioactivity of homologous molecules in mice, and production in laboratory animals of antibodies to human proteins limit preclinical evaluation of such molecules. In clinical trials, rhuGM-CSF was efficacious and well tolerated. The derivation of the recombinant molecule, optimal dosing, scheduling, and confounding effects of concurrent disease and treatments are factors that influence efficacy, adverse responses, and immunogenicity reported in patients treated with CSFs. In comparisons of yeast-derived with Escherichia coli-derived rhuGM-CSF, the reduced severity and frequency of all adverse events, preponderance of low-grade adverse events, and similarity of positive clinical response versus adverse events reported for granulocyte CSF support safety and efficacy of yeast-derived rhuGM-CSF Enhanced pharmacoeconomic evaluations are beginning to limit and redirect clinical applications in this class of biological agents.

Key Words: Recombinant hematopoietic growth factors • IL-3 • fusion protein • PIXY321 • safety assessment • in vitro • preclinical • clinical

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				P. Singri, D. P. West, and K. B. Gordon Biologic Therapy for Psoriasis: The New Therapeutic Frontier Arch Dermatol, May 1, 2002; 138(5): 657 - 663. [Abstract] [Full Text] [PDF]